dutasteride
Trade name: avodart
Approved
Nov 20, 2001
Dutasteride is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase (5AR), intracellular enzymes that convert testosterone to 5 alpha-dihydrotestosterone (DHT). Type I 5a-reductase is predominant in the sebaceous glands of most regions of skin, including scalp, and liver. Type I 5a-reductase is responsible for approximately one-third of circulating DHT. The Type II 5a-reductase isozyme is primarily found in prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT. Dutasteride inhibits the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT), which is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. Dutasteride is a competitive and specific inhibitor of both type 1 and type 2 5 alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow. Used for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for surgery. Marketed under the brand name Avodart. — NCATS
Clinical trial activity
103 trials · 80 clinical orgs · 38 marketing orgs
Earliest trial started Nov 1, 2002 (NCT00493987)
Timeline
2000s
- Nov 20, 2001
GlaxoSmithKline — Earliest FDA Approval
- Nov 20, 2001
GlaxoSmithKline — NDA Organization
- Nov 20, 2001
Woodward — NDA Secondary Org
- Nov 20, 2001
Waylis Therap — NDA Secondary Org
- Jan 1, 2003
GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
2010s
- Dec 21, 2010
Barr Laboratories — Marketing Organization
- Dec 21, 2010
Teva — Marketing Organization
- Feb 26, 2014
Anchen Pharmaceuticals, Inc — Marketing Organization
- Feb 26, 2014
Par Pharmaceuticals — Marketing Organization
- Feb 26, 2014
PH HEALTH — Marketing Organization
- Nov 20, 2015
Actavis — Marketing Organization
- Nov 20, 2015
Amneal Pharmaceuticals — Marketing Organization
- Nov 20, 2015
Aurobindo Pharma — Marketing Organization
- Nov 20, 2015
Bionpharma Inc — Marketing Organization
- Nov 20, 2015
Rising Pharmaceuticals — Marketing Organization
- Nov 20, 2015
Strides Pharma Science — Marketing Organization
- Nov 20, 2015
Vintage — Marketing Organization
- Nov 20, 2015
Nostrum Laboratories — Marketing Organization
- Nov 20, 2015
ANDA Repository — Marketing Organization
- Nov 20, 2015
Esteve Labs — Marketing Organization
- Nov 20, 2015
Apax Partners — Marketing Organization
- Nov 20, 2015
Allergan PLC (2015) — Marketing Organization
- Nov 20, 2015
Chartwell Pharmaceuticals — Marketing Organization
- Nov 20, 2015
ONESOURCE SPECIALTY — Marketing Organization
- Nov 20, 2015
PHARMOBEDIENT — Marketing Organization
- Nov 23, 2015
West-Ward Pharmaceutical — Marketing Organization
- Nov 23, 2015
Hikma — Marketing Organization
- Nov 24, 2015
Apotex — Marketing Organization
- Mar 17, 2016
Intergel Pharms Inc — Marketing Organization
- Mar 17, 2016
Acella Pharmaceuticals — Marketing Organization
- Jun 14, 2016
Mylan — Marketing Organization
- Oct 21, 2016
Ascent Pharmahealth — Marketing Organization
- Apr 7, 2017
Marksans Pharma — Marketing Organization
- Apr 7, 2017
Adaptis Pharma — Marketing Organization
- Oct 4, 2017
Cadila Healthcare — Marketing Organization
- Oct 13, 2017
Heritage Pharma — Marketing Organization
- Oct 13, 2017
Emcure — Marketing Organization
- Nov 21, 2017
Yichang Humanwell Pharmaceutical Co.,Ltd — Marketing Organization
- May 24, 2018
Zydus Discovery DMCC — Marketing Organization
- Jun 22, 2018
Pharmaceutics International, Inc. — Marketing Organization
Indications
Approved for
Studied for
- Aging · Phase 1
- Alcoholism · Phase 4
- Alopecia · Phase 3
- Amyotrophic Lateral Sclerosis · Phase 2
- Bulbo-Spinal Atrophy, X-Linked · Phase 2
- Carcinoma · Phase 2
- Contraception · Phase 2
- COVID-19 · Phase 2/Phase 3
- Deficiency Diseases · Phase 2
- Depression · Phase 1
- Dutasteride · Phase 2/Phase 3
- Erectile Dysfunction · Phase 3
- Eunuchism · Phase 2
- Healthy Volunteers · Phase 4
- Hypogonadism · Phase 4
- Lower Urinary Tract Symptoms · Phase 2
- Neoplasms · Phase 2
- Premenstrual Syndrome · Phase 1
- Prostatitis · Phase 3
- Sexual Dysfunction, Physiological · Phase 3
- Transsexualism · Phase 3
- Urologic Diseases · Phase 1
Mechanism of action
Combination products
jalyn
with tamsulosin
Approval history
- approvedNov 20, 2001
Chemistry & pharmacology
SMILES
C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC5=CC(=CC=C5C(F)(F)F)C(F)(F)F- Mol. weight
- 528.5297 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaDutasteride ↗
- NCATSO0J6XJN02I ↗
- ChEMBLCHEMBL1200969 ↗
Also known as
- (5alpha,17beta)-n-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
- (5alpha,17beta)-n-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
- alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
- alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
- avodart
- avodart
- avodart
- avodart
- avodart
- avolve
- dutasteride
- dutasteride
- dutasteride
- dutasteride
- dutasteride
- dutasteride
- dutasteride
- dutasteride
- dutasteride
- dutasteride
- dutasteride
- gg745
- gg-745
- gg-745
- gg-745
- gi-198745
- gi-198745
- veltride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06916793 | Phase 3 | Apr 30, 2025 | Chong Kun Dang Pharmaceutical, Seoul National University |
| NCT06264414 | Phase 3 | Feb 28, 2025 | EMS S/A |
| NCT06233227 | Phase 1 | Sep 24, 2024 | Bio-innova Co., Ltd |
| NCT07065682 | Phase 1 | Jul 1, 2023 | Diponegoro University |
| NCT05705700 | Phase 2 | Feb 28, 2023 | University of Minnesota |
| NCT06001619 | Phase 4 | Dec 1, 2022 | University of Turku |
| NCT05599243 | Phase 2 | Sep 29, 2022 | Universidad Complutense de Madrid |
| NCT05513365 | Phase 2 | Sep 20, 2022 | Radboud University, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT04947631 | Phase 3 | Jul 31, 2021 | Dongkook Pharmaceutical Co., Ltd. |
| NCT04825561 | Phase 3 | Jun 9, 2021 | Addpharma Inc. |
| NCT04677855 | Phase 1 | Mar 30, 2021 | Pellficure Pharmaceuticals, Inc |
| NCT04654689 | Phase 2 | Jan 31, 2021 | Fundación Universidad Católica de Valencia San Vicente Mártir, Universidad Católica de Valencia |
| NCT04729491 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2020 | Applied Biology, Inc., Brown University, Corpometria Institute |
| NCT04214808 | Phase 1 | Jan 3, 2020 | Addpharma Inc., Kyungpook University |
| NCT04098302 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2019 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Connecticut |
| NCT04756206 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2019 | Ain Shams University |
| NCT03240939 | Phase 1 | Mar 27, 2017 | University of Ulsan, Yuyu Pharma, Inc. |
| NCT02147964 | Phase 2 | Jan 1, 2017 | University of Washington |
| NCT02839122 | Phase 1 | May 1, 2016 | AIDS Malignancy Consortium, Yuyu Pharma, Inc. |
| NCT06677177 | N/A | Feb 16, 2016 | University of Sulaimani |
Organizations
Research & Development (80)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 49 | 31 | 5 | 2003 |
| National Institutes of Health (NIH) | Government | 8 | 2 | 4 | 2002 |
| University of Washington | Academic/Hospital | 7 | 7 | 3 | 2005 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 5 | 0 | 3 | 2006 |
| University of Connecticut | Academic/Hospital | 5 | 5 | 3 | 2006 |
| Harvard University | Academic/Hospital | 4 | 4 | 1 | 2005 |
| Dongkook Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2013 |
| University of Rochester | Academic/Hospital | 3 | 1 | 2 | 2005 |
| Addpharma Inc. | For profit | 2 | 2 | 2 | 2020 |
| Brown University | Academic/Hospital | 2 | 1 | 2 | 2008 |
| Department of Veteran Affairs | Government | 2 | 1 | 2 | 2004 |
| Johns Hopkins University | Academic/Hospital | 2 | 1 | 1 | 2005 |
| Laval University | Academic/Hospital | 2 | 2 | 2 | 2009 |
| Northwestern University | Academic/Hospital | 2 | 1 | 2 | 2006 |
| Seoul National University | Academic/Hospital | 2 | 1 | 2 | 2008 |
| Unita Complessa di Ostetricia e Ginecologia | Academic/Hospital | 2 | 2 | 1 | 2005 |
| University of Chicago | Academic/Hospital | 2 | 2 | 2 | 2007 |
| Yuyu Pharma, Inc. | For profit | 2 | 2 | 1 | 2016 |
| AIDS Malignancy Consortium | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2019 |
Marketing (48)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ANDA Repository | For profit | MKTG | Nov 20, 2015 |
| Acella Pharmaceuticals | For profit | MKTG | Mar 17, 2016 |
| Actavis | For profit | MKTG | Nov 20, 2015 |
| Adaptis Pharma | For profit | MKTG | Apr 7, 2017 |
| Allergan PLC (2015) | For profit | MKTG | Nov 20, 2015 |
| Amneal Pharmaceuticals | For profit | MKTG | Nov 20, 2015 |
| Anchen Pharmaceuticals, Inc | For profit | MKTG | Feb 26, 2014 |
| Apax Partners | For profit | MKTG | Nov 20, 2015 |
| Apotex | For profit | MKTG | Nov 24, 2015 |
| Apotex | For profit | SYN | Nov 24, 2015 |
| Ascent Pharmahealth | For profit | MKTG | Oct 21, 2016 |
| Aurobindo Pharma | For profit | SYN | Nov 20, 2015 |
| Aurobindo Pharma | For profit | MKTG | Nov 20, 2015 |
| Aurobindo Pharma | For profit | SYN | Jul 18, 2024 |
| Barr Laboratories | For profit | MKTG | Dec 21, 2010 |
| Bionpharma Inc | For profit | MKTG | Nov 20, 2015 |
| Bionpharma Inc | For profit | SYN | Nov 20, 2015 |
| Cadila Healthcare | For profit | MKTG | Oct 4, 2017 |
| Chartwell Pharmaceuticals | For profit | MKTG | Nov 20, 2015 |
| Emcure | For profit | MKTG | Oct 13, 2017 |
| Esteve Labs | For profit | SYN | Nov 20, 2015 |
| Esteve Labs | For profit | MKTG | Nov 20, 2015 |
| GlaxoSmithKline | For profit | NDA | Nov 20, 2001 |
| Heritage Pharma | For profit | MKTG | Oct 13, 2017 |
| Hikma | For profit | MKTG | Nov 23, 2015 |
| Hikma | For profit | SYN | Nov 23, 2015 |
| Intergel Pharms Inc | For profit | MKTG | Mar 17, 2016 |
| Marksans Pharma | For profit | MKTG | Apr 7, 2017 |
| Mylan | For profit | MKTG | Jun 14, 2016 |
| Mylan | For profit | SYN | Jun 14, 2016 |
| Nostrum Laboratories | For profit | MKTG | Nov 20, 2015 |
| ONESOURCE SPECIALTY | For profit | MKTG | Nov 20, 2015 |
| PH HEALTH | For profit | MKTG | Feb 26, 2014 |
| PHARMOBEDIENT | For profit | MKTG | Nov 20, 2015 |
| Par Pharmaceuticals | For profit | MKTG | Feb 26, 2014 |
| Pharmaceutics International, Inc. | For profit | MKTG | Jun 22, 2018 |
| Rising Pharmaceuticals | For profit | MKTG | Nov 20, 2015 |
| Rising Pharmaceuticals | For profit | SYN | Nov 20, 2015 |
| Strides Pharma Science | For profit | MKTG | Nov 20, 2015 |
| Teva | For profit | MKTG | Dec 21, 2010 |
| Vintage | For profit | MKTG | Nov 20, 2015 |
| Vintage | For profit | SYN | Nov 20, 2015 |
| Waylis Therap | For profit | NDA2 | Nov 20, 2001 |
| West-Ward Pharmaceutical | For profit | MKTG | Nov 23, 2015 |
| Woodward | For profit | NDA2 | Nov 20, 2001 |
| Yichang Humanwell Pharmaceutical Co.,Ltd | For profit | MKTG | Nov 21, 2017 |
| Zydus Discovery DMCC | For profit | MKTG | May 24, 2018 |
| Zydus Discovery DMCC | For profit | SYN | Oct 4, 2017 |